Table of Content

Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Information Sources
Methodology
Geographic Breakdown
Analyst’s Credentials

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background
Monoclonal Antibodies
History of Monoclonal Antibodies
Advantages and Disadvantages of Monoclonal Antibodies
Monoclonal Antibodies in Oncology
Types of Monoclonal Antibodies

Chapter 4 Market Dynamics
Market Drivers
Increasing Incidence of Cancer
New Product Launches
Rising Healthcare Expenditures and Government Funding
Licensing and Collaboration Agreements
Market Barriers
Price Controls
Regulatory Approval Pressures
Entry of Biosimilars
Opportunities
Impact of COVID-19

Chapter 5 Market Breakdown by Type
Types of Monoclonal Antibodies for Oncology
Market Overview
Market Revenue
Global Market for Monoclonal Antibodies in Oncology by Type
Humanized Monoclonal Antibodies
Human Monoclonal Antibodies
Chimeric Monoclonal Antibodies

Chapter 6 Market Breakdown by Application
Overview
Lung Cancer
Market Size and Forecast
Breast Cancer
Market Size and Forecast
Colorectal Cancer
Market Size and Forecast
Blood Cancer
Market Size and Forecast
Other Cancers
Market Size and Forecast

Chapter 7 Market Breakdown by Region
Introduction
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
India
Japan
Rest of Asia-Pacific
Rest of the World
Market Size and Forecast

Chapter 8 Regulatory Aspects
New Approvals of Monoclonal Antibodies for Oncology
Recalls, Withdrawals, and Safety Alerts

Chapter 9 Patent Review/ New Developments
New Developments
Phase I Clinical Trials
Phase II Clinical Trials
Phase III Clinical Trials

Chapter 10 Competitive Landscape
Mergers, Acquisitions, and Collaborations
Company Market Shares

Chapter 11 Company Profiles
AMGEN INC.
ASTRAZENECA PHARMACEUTICALS
BRISTOL-MYERS SQUIBB
ELI LILLY
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE
GILEAD SCIENCES INC.
JOHNSON & JOHNSON
MERCK & CO. INC.
MERCK KGAA
PFIZER INC.
SANOFI S.A.
SEAGEN



List of Figures

 

Summary Figure A : Global Market for Monoclonal Antibodies in Oncology, 2020-2027
Summary Figure B : Global Market for Monoclonal Antibodies in Oncology, by Type, 2020-2027
Figure 1 : Approved Antibody Therapeutics in the U.S. and EU, 2010-2021
Figure 2 : Global Estimated New Cancer Cases, by Region, 2020 vs. 2040
Figure 3 : Global Market for Monoclonal Antibodies in Oncology, by Type, 2020-2027
Figure 4 : Global Market Shares of Monoclonal Antibodies in Oncology, by Type, 2021
Figure 5 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 6 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 7 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 8 : Global Market for Monoclonal Antibodies in Oncology, by Application, 2020-2027
Figure 9 : Global Market Shares of Monoclonal Antibodies in Oncology, by Application, 2021
Figure 10 : Global Market for Monoclonal Antibodies for Lung Cancer, by Region, 2020-2027
Figure 11 : Global Market for Monoclonal Antibodies for Breast Cancer, by Region, 2020-2027
Figure 12 : Global Market for Monoclonal Antibodies for Colorectal Cancer, by Region, 2020-2027
Figure 13 : Global Market for Monoclonal Antibodies for Blood Cancer, by Region, 2020-2027
Figure 14 : Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, 2020-2027
Figure 15 : Global Market for Monoclonal Antibodies in Oncology, by Region, 2020-2027
Figure 16 : Global Market Shares of Monoclonal Antibodies in Oncology, by Region, 2021
Figure 17 : North American Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 18 : U.S. Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 19 : Canadian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 20 : European Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 21 : German Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 22 : U.K. Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 23 : French Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 24 : Italian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 25 : Spanish Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 26 : Rest of European Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 27 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, 2020-2027
Figure 28 : Chinese Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 29 : Indian Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 30 : Japanese Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 31 : Rest of Asia-Pacific Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 32 : Rest of the World Market for Monoclonal Antibodies in Oncology, 2020-2027
Figure 33 : Global Manufacturer/Supplier Market Shares of Monoclonal Antibodies in Oncology, 2021
Figure 34 : Amgen: Annual Revenue, 2019-2021
Figure 35 : Amgen: Total Sales Share, by Product, 2021
Figure 36 : Amgen: Total Revenue Share, by Region, 2021
Figure 37 : AstraZeneca: Annual Revenue, 2019-2021
Figure 38 : AstraZeneca: Total Sales Share, by Segment, 2021
Figure 39 : AstraZeneca: Total Revenue Share, by Region, 2021
Figure 40 : Bristol-Myers Squibb: Annual Revenue, 2019-2021
Figure 41 : Bristol Myers Squibb: Total Sales Share, by Product, 2021
Figure 42 : Bristol-Myers Squibb: Total Revenue Share, by Region, 2021
Figure 43 : Eli Lilly: Annual Revenue, 2019-2021
Figure 44 : Eli Lilly: Total Sales Share, by Product Segment, 2021
Figure 45 : Eli Lilly: Total Revenue Share, by Region, 2021
Figure 46 : F. Hoffmann-La Roche: Annual Revenue, 2019-2021
Figure 47 : F. Hoffmann-La Roche: Total Sales Share, by Pharmaceutical Segment, 2021
Figure 48 : F. Hoffmann-La Roche: Total Revenue Share, by Region, 2021
Figure 49 : Johnson & Johnson: Annual Revenue, 2019-2021
Figure 50 : Johnson & Johnson: Total Sales Share, by Business Segment, 2021
Figure 51 : Johnson & Johnson: Total Revenue Share, by Region, 2021
Figure 52 : Merck & Co. Inc.: Annual Revenue, 2019-2021
Figure 53 : Merck & Co. Inc.: Revenue Share, by Business Segment, 2021
Figure 54 : Merck & Co. Inc.: Revenue Share, by Region, 2021
Figure 55 : Pfizer: Annual Revenue, 2019-2021
Figure 56 : Pfizer: Net Sales Share, by Business Segment, 2021
Figure 57 : Pfizer: Net Sales Share, by Region, 2021

List of Tables

 

Summary Table A : Global Market for Monoclonal Antibodies in Oncology, Through 2027
Summary Table B : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027
Table 1 : Evolution of Monoclonal Antibodies
Table 2 : Advantages and Disadvantages of Monoclonal Antibodies
Table 3 : Monoclonal Antibodies Approved for Oncology
Table 4 : Murine Monoclonal Antibodies
Table 5 : Chimeric Monoclonal Antibodies
Table 6 : Humanized Monoclonal Antibodies
Table 7 : Human Monoclonal Antibodies
Table 8 : Total Number of New Cases and Deaths Due to Various Cancers Globally, 2020
Table 9 : Funding, by Research Areas, 2020
Table 10 : Global Market for Monoclonal Antibodies in Oncology, by Type, Through 2027
Table 11 : Global Market for Humanized Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 12 : Global Market for Human Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 13 : Global Market for Chimeric Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 14 : Global Market for Monoclonal Antibodies in Oncology, by Application, Through 2027
Table 15 : Global Market Market for Monoclonal Antibodies for Lung Cancer, by Region, Through 2027
Table 16 : Global Market Market for Monoclonal Antibodies for Breast Cancer, by Region, Through 2027
Table 17 : Global Market Market for Monoclonal Antibodies for Colorectal Cancer, by Region, Through 2027
Table 18 : Global Market Market for Monoclonal Antibodies for Blood Cancer, by Region, Through 2027
Table 19 : Numbers for All Cancers (Except Non-Melanoma Skin Cancer), 2020
Table 20 : Global Market for Monoclonal Antibodies for Other Types of Blood Cancer, by Region, Through 2027
Table 21 : Global Market for Monoclonal Antibodies in Oncology, by Region, Through 2027
Table 22 : North American Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 23 : Cancer Incidence and Mortality, Age Standardized Rate, per 100,000, by Cancer Type, EU Countries, 2020
Table 24 : European Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 25 : Asia-Pacific Market for Monoclonal Antibodies in Oncology, by Country, Through 2027
Table 26 : Newly Approved Monoclonal Antibodies for Oncology, 2019-April 2022
Table 27 : Recalls, Withdrawals, and Safety Alerts, 2019-April 2022
Table 28 : Monoclonal Antibodies for Oncology in Phase I Clinical Trials
Table 29 : Monoclonal Antibodies for Oncology in Phase II Clinical Trials
Table 30 : Monoclonal Antibodies for Oncology in Phase III Clinical Trials
Table 31 : M&A: Pharmaceutical Companies
Table 32 : Sales of Blockbuster Monoclonal Antibodies for Oncology, 2021
Table 33 : Amgen: Financial Performance, 2019-2021
Table 34 : AstraZeneca: Financial Performance, 2019-2021
Table 35 : AstraZeneca: Business Segment
Table 36 : Bristol-Myers Squibb: Financial Performance, 2019-2021
Table 37 : Eli Lilly: Business Segments
Table 38 : Eli Lilly: Financial Performance, 2019-2021
Table 39 : F. Hoffmann-La Roche: Business Segments
Table 40 : F. Hoffmann-La Roche: Financial Performance, 2019-2021
Table 41 : Johnson & Johnson: Business Segments
Table 42 : Johnson & Johnson: Financial Performance, 2019-2021
Table 43 : Merck & Co. Inc.: Business Segment
Table 44 : Merck & Co. Inc.: Financial Performance, 2019-2021
Table 45 : Pfizer: Business Segment
Table 46 : Pfizer: Financial Performance, 2019-2021
Table 47 : Sanofi: Business Segments